# OncoC4

> OncoC4, Inc. is a privately held, late clinical-stage biopharmaceutical company in Rockville, Maryland (founded 2020) developing novel biologics for cancer across the CTLA-4, CD24, PD-1/VEGF and Siglec immune-checkpoint pathways. Its lead candidate is gotistobart (BNT316/ONC-392), a next-generation anti-CTLA-4 antibody co-developed with BioNTech. OncoC4 publishes no public API, SDK, developer portal or developer documentation.

Generated by API Evangelist from the public OncoC4 web surface on 2026-08-04.
method: generated
source: https://oncoc4.com/en/

## API surface

OncoC4 has no developer program. There is no public API, no OpenAPI or AsyncAPI
description, no GraphQL endpoint, no MCP server, no A2A agent card, no SDK in any
package registry (npm, PyPI, RubyGems, crates.io, NuGet, Packagist all return zero
results for "oncoc4"), and no GitHub organization. The subdomains api.oncoc4.com,
developer.oncoc4.com and docs.oncoc4.com do not resolve.

The only machine-readable endpoints served on oncoc4.com are Umbraco CMS defaults
for website member authentication, not an API product:

- [OpenID Connect discovery](https://oncoc4.com/.well-known/openid-configuration): OAuth 2.0 / OIDC metadata for the Umbraco Delivery API member authorization server.
- [OAuth 2.0 authorization server metadata](https://oncoc4.com/.well-known/oauth-authorization-server): RFC 8414 document, byte-identical to the OIDC one.
- [JWKS](https://oncoc4.com/.well-known/jwks): RS256 public signing keys.

The endpoints those documents advertise live under `/umbraco/`, which
https://oncoc4.com/robots.txt disallows.

## Company

- [Home](https://oncoc4.com/en/): Company overview.
- [About](https://oncoc4.com/en/about-us/): Mission, leadership and company profile.
- [History](https://oncoc4.com/en/about-us/history/): Company timeline.
- [Collaboration](https://oncoc4.com/en/about-us/collaboration/): Partnerships, including the March 2023 BioNTech collaboration on BNT316/ONC-392.
- [Sites and subsidiaries](https://oncoc4.com/en/about-us/sites-and-subsidiaries/): US headquarters plus subsidiaries in Nanjing, Guangzhou and Beijing, China, and Brisbane, Australia.
- [Contact](https://oncoc4.com/en/contact/): Headquarters at 9640 Medical Center Drive, Rockville, MD 20850, USA; general, investor and media inquiry addresses.
- [Careers](https://oncoc4.com/en/careers/): Hiring overview.
- [Job opportunities](https://oncoc4.com/en/careers/job-opportunities/): Open roles.

## Science and pipeline

- [Pipeline](https://oncoc4.com/en/pipeline/pipeline/): Development-stage overview of the candidate portfolio.
- [Clinical trials](https://oncoc4.com/en/pipeline/clinical-trials/): Trials in progress.
- [CTLA-4 program](https://oncoc4.com/en/our-scientific/ctla-4-program/): Lead program; pH-dependent anti-CTLA-4 antibody that lets CTLA-4 recycle.
- [PD-1/VEGF program](https://oncoc4.com/en/our-scientific/pd-1vegf/): Bispecific program.
- [Siglec programs](https://oncoc4.com/en/our-scientific/siglec-programs/): Siglec-targeting programs.
- [CD24 platform](https://oncoc4.com/en/our-scientific/cd24-platform/): CD24 "don't eat me" checkpoint platform.

## News and resources

- [News](https://oncoc4.com/en/news-resources/news/): Company announcements.
- [Resources](https://oncoc4.com/en/news-resources/resources/): Publications, posters and presentations (27 publications, 10 posters, 5 presentations as of 2026-08-04), filterable by type and year.

## Policies

- [Privacy policy](https://oncoc4.com/en/privacy-policy/)
- [Cookie policy](https://oncoc4.com/en/cookie-policy/)
- [Accessibility](https://oncoc4.com/en/accessibility/)
- [Expanded access policy](https://oncoc4.com/en/expanded-access-policy/): Policy on pre-approval access to investigational therapies.

## Optional

- [LinkedIn](https://www.linkedin.com/company/oncoc4)
- [Simplified Chinese site](https://oncoc4.com/cn/)
- [Traditional Chinese site](https://oncoc4.com/hk/)